#Switzerland #HealthTech #Lausanne #Xsensio #Biosensing

Xsensio SA Raises $7M in Oversubscribed Series A Funding

Xsensio SA, a cutting-edge Swiss deep-tech company specializing in near real-time continuous biochemical monitoring, has announced a significant financial milestone. The company successfully closed a $7 million oversubscribed Series A financing round, which has drawn interest from various investors, including the San Francisco-based WI Harper venture capital firm, Privilège Ventures, and several private investors from the United States, Europe, and Asia.

Pioneering Development of Continuous Monitoring Technology

The recent funding will expedite the development and clinical validation of Xsensio's innovative Lab-on-Skin© biosensing platform. This unique wearable technology is designed to deliver dynamic, multi-modal biochemical information, which is intended to facilitate clinical decision-making both within hospital settings and beyond.

Esmeralda Megally, CEO of Xsensio, emphasized the importance of this Series A funding, stating, "This milestone marks a crucial step in bringing continuous biochemical monitoring to real clinical environments. For the first time, clinicians will have access to vital data in real time, something that has traditionally been unavailable at the point of care. This breakthrough has the potential to transform the monitoring and treatment of patients."

Strategic Collaboration for Enhanced Scalability

In conjunction with this funding announcement, Xsensio also revealed a long-term partnership with Texas Instruments, a global leader in semiconductor technology. This strategic collaboration is expected to leverage expertise in CMOS integration and miniaturization, enhancing the manufacturability of biosensing systems. Adrian Ionescu, CTO of Xsensio, commented on the partnership, stating, "The collaboration with Texas Instruments significantly enhances our access to advanced semiconductor technology. By merging our biosensing innovations with top-tier semiconductor capabilities, we aim to create a platform that not only has a clinical impact but also supports cost-effective deployment on a large scale."

Investors See Long-Term Value in Xsensio

WI Harper's Partner, Wilson Wu, expressed confidence in Xsensio's potential, noting, "We believe Xsensio is pioneering a novel category within wearable biosensing technology. Given the company's remarkable progress and immense market potential, we are thrilled to lead this investment round. Continuous biochemical monitoring is shifting the paradigm from sporadic measurements to real-time insights, and Xsensio is strategically positioned to lead this change."

Jaqueline Ruedin Rüsch, Chair of the Board, echoed these sentiments by recognizing the significant transformational potential that continuous biochemical monitoring technology holds within the healthcare field.

About Xsensio SA

Founded as a spinoff from premier academic research, Xsensio is dedicated to the advancement of its Lab-on-Skin© wearable biosensing platform. The company is committed to delivering ongoing, real-time biochemical data for personalized healthcare and preventive medical practices. Collaborating with leading hospitals and industrial partners, Xsensio aims to advance clinically relevant biosensing technologies to improve patient outcomes both in hospitals and in the broader community. In recognition of its innovation, Xsensio has been featured in TIME magazine as one of the World's Top HealthTech Companies of 2025.

For more information, please visit Xsensio’s official website.